AC Immune Statistics
Total Valuation
AC Immune has a market cap or net worth of $345.21 million. The enterprise value is $230.88 million.
| Market Cap | 345.21M |
| Enterprise Value | 230.88M |
Important Dates
The next estimated earnings date is Friday, August 2, 2024, before market open.
| Earnings Date | Aug 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AC Immune has 99.20 million shares outstanding.
| Shares Outstanding | 99.20M |
| Owned by Insiders (%) | 41.87% |
| Owned by Institutions (%) | 29.93% |
| Float | 41.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.52 |
| Forward PS | 6.42 |
| PB Ratio | 2.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.78, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.78 |
| Quick Ratio | 7.48 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -473.57 |
Financial Efficiency
Return on equity (ROE) is -38.30% and return on invested capital (ROIC) is -37.92%.
| Return on Equity (ROE) | -38.30% |
| Return on Assets (ROA) | -33.60% |
| Return on Capital (ROIC) | -37.92% |
| Revenue Per Employee | $104,468 |
| Profits Per Employee | -$385,248 |
| Employee Count | 161 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AC Immune has paid $7,885 in taxes.
| Income Tax | 7,885 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.62% in the last 52 weeks. The beta is 1.27, so AC Immune's price volatility has been higher than the market average.
| Beta (5Y) | 1.27 |
| 52-Week Price Change | +15.62% |
| 50-Day Moving Average | 3.82 |
| 200-Day Moving Average | 3.39 |
| Relative Strength Index (RSI) | 40.47 |
| Average Volume (20 Days) | 234,535 |
Short Selling Information
| Short Interest | 731,117 |
| Short Previous Month | 801,371 |
| Short % of Shares Out | 1.38% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, AC Immune had revenue of $16.82 million and -$62.03 million in losses. Loss per share was -$0.69.
| Revenue | 16.82M |
| Gross Profit | 16.67M |
| Operating Income | -63.22M |
| Pretax Income | -61.48M |
| Net Income | -62.03M |
| EBITDA | -58.87M |
| EBIT | -61.35M |
| Loss Per Share | -$0.69 |
Balance Sheet
The company has $118.08 million in cash and $3.75 million in debt, giving a net cash position of $114.33 million or $1.15 per share.
| Cash & Cash Equivalents | 118.08M |
| Total Debt | 3.75M |
| Net Cash | 114.33M |
| Net Cash Per Share | $1.15 |
| Equity (Book Value) | 162.98M |
| Book Value Per Share | 1.64 |
| Working Capital | 107.86M |
Cash Flow
In the last 12 months, operating cash flow was -$48.84 million and capital expenditures -$957,500, giving a free cash flow of -$49.79 million.
| Operating Cash Flow | -48.84M |
| Capital Expenditures | -957,500 |
| Free Cash Flow | -49.79M |
| FCF Per Share | -$0.50 |
Margins
Gross margin is 99.13%, with operating and profit margins of -375.87% and -368.77%.
| Gross Margin | 99.13% |
| Operating Margin | -375.87% |
| Pretax Margin | -365.52% |
| Profit Margin | -368.77% |
| EBITDA Margin | -350.00% |
| EBIT Margin | -364.74% |
| FCF Margin | -296.06% |
Dividends & Yields
AC Immune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.63% |
| Shareholder Yield | -18.63% |
| Earnings Yield | -17.97% |
| FCF Yield | -14.42% |
Analyst Forecast
The average price target for AC Immune is $12.00, which is 244.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.00 |
| Price Target Difference | 244.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 49.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AC Immune has an Altman Z-Score of 5.05 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.05 |
| Piotroski F-Score | 3 |